

09 M.S  
H3554



**SYSTEMIC INFLAMMATORY  
RESPONSE SYNDROME  
AND SEPSIS IN  
MAJOR VASCULAR SURGERY**

*Tiffany Alicia Hassen, MBBS.*

**Thesis Submitted to The University of Adelaide  
for the Degree of Master of Surgery,  
January 2006.**

This work was undertaken within the Department of Surgery,  
The University of Adelaide, The Queen Elizabeth Hospital, Adelaide, Australia

# Table of Contents

## CHAPTER 1: INTRODUCTION, LITERATURE REVIEW AND AIMS OF CURRENT STUDY

1.1 Introduction .....	1
1.2 Systemic Inflammatory Response Syndrome (SIRS) and Sepsis .....	7
1.2.1 Pathophysiology of SIRS.....	7
1.2.2 Polymorphonuclear Leukocyte Priming .....	15
1.2.3 Definition of Systemic Inflammatory Response Syndrome (SIRS) .....	17
1.2.4 Definition of Sepsis .....	18
1.2.5 Relevance of SIRS and Sepsis in Major Vascular Surgery .....	19
1.3 Polymorphonuclear Leukocyte Integrin and Immunoglobulin G Fc Receptors ..	24
1.3.1 CD11/CD18 Leukocyte Adhesion Molecules .....	24
1.3.1.1 Structure and Distribution.....	24
1.3.1.2 Function .....	26
1.3.1.3 CD11b and Clinical Outcomes .....	27
1.3.1.4 CD11b and AAA Repair.....	31
1.3.2 Immunoglobulin G Fc Receptors (Fc $\gamma$ R) .....	32
1.3.2.1 Fc $\gamma$ R Classification .....	33
1.3.2.2 Fc $\gamma$ R Structure and Signalling .....	34
1.3.2.3 Fc $\gamma$ R Cell Distribution and Expression.....	35
1.3.2.4 Leukocyte Fc $\gamma$ R Function .....	36
1.3.2.5 PMN Fc $\gamma$ RI (CD64) and Fc $\gamma$ RIII (CD16) Expression in Clinical Practice.....	37
1.3.2.6 Fc $\gamma$ RIIa (CD32a) and Fc $\gamma$ RIIIb (CD16b) Polymorphisms .....	41

1.3.3 Influence of Genetic Polymorphisms on Operative Risk and Sepsis .....	44
1.4 Cytokines.....	49
1.4.1 Cytokines: An Overview .....	49
1.4.2 Cytokine Biology.....	51
1.4.2.1 Tumour necrosis factor- $\alpha$ (TNF- $\alpha$ ) .....	51
1.4.2.2 Interleukin-1 $\beta$ (IL-1 $\beta$ , IL-1F2) .....	53
1.4.2.3 Interleukin-6 (IL-6).....	54
1.4.2.4 Interleukin-10 (IL-10).....	55
1.4.2.5 Interleukin-12 (IL-12, IL-12p70).....	57
1.4.2.6 Chemokines .....	58
1.4.2.6.1 Interleukin-8 (IL-8, CXCL8) .....	59
1.4.3 Generation of Cytokines in Major Vascular Surgery .....	61
1.4.3.1 Ischaemia and Reperfusion Injury (IRI) .....	61
1.4.3.2 The Vascular Endothelium .....	62
1.4.3.3 Lower Limbs and Gastrointestinal Tract .....	62
1.4.3.4 Kidneys .....	64
1.4.3.5 Cytokine Generation in EVAR .....	64
1.4.4 Cytokines and the Prediction of Clinical Outcomes.....	65
1.5 Nutritional Status and Surgical Outcomes .....	70
1.5.1 Definitions .....	70
1.5.2 Frequency of Malnutrition.....	70
1.5.3 Malnutrition and Surgical Outcomes.....	71
1.6 The Neuroendocrine Response to Surgical Stress.....	75
1.6.1 The Hypothalamo-pituitary-adrenocortical (HPA) Axis .....	75
1.6.2 The Sympathetic Nervous System.....	77

1.7 Psychological Influences on Surgical Response and Outcome .....	79
1.7.1 Depression .....	79
1.7.1.1 Prevalence of Depressive Disorder .....	79
1.7.1.2 Depression and Adverse Disease Outcomes.....	79
1.7.1.2.1 Depression and Health-related Quality of Life (HRQoL).....	80
1.7.1.2.3 Depression and Immune Dysregulation.....	81
1.7.1.2.4 Neuroendocrine Features of Depression.....	82
1.7.2 Anxiety .....	82
1.8 Immune and Neuroendocrine Responses in Open AAA Repair Compared to EVAR .....	84
1.8.1 The Immuno-inflammatory Response .....	84
1.8.2 The Neuroendocrine Response .....	87
1.9 Aims of Current Study .....	89

## **CHAPTER 2: METHODS**

2.1 Approval and Informed Consent .....	91
2.2 Patients .....	92
2.2.1 Inclusion Criteria .....	92
2.2.2 Exclusion Criteria .....	92
2.2.3 Withdrawal Criteria .....	93
2.2.4 Open Aortic Aneurysm Repair ('Open') Cohort.....	94
2.2.4.1 Inclusions and Exclusions.....	94
2.2.4.2 Patient Characteristics and Aneurysm Morphology .....	94
2.2.4.3 Anaesthetic Management.....	96
2.2.4.4 Operative Management.....	97

2.2.4.5 Post-operative Management .....	99
2.2.5 Endovascular Aortic Aneurysm Repair (EVAR) Cohort .....	100
2.2.5.1 Inclusions and Exclusions.....	100
2.2.5.2 Patient Characteristics and Aneurysm Morphology .....	100
2.2.5.3 Anaesthetic Management.....	100
2.2.5.4 Operative Management.....	101
2.2.5.5 Post-operative Management .....	102
2.2.6 Lower Limb Revascularisation ('Lower Limb') Cohort .....	102
2.2.6.1 Inclusions and Exclusions.....	102
2.2.6.2 Patient Characteristics and Lower Limb Pathology .....	103
2.2.6.3 Anaesthetic Management.....	103
2.2.6.4 Pre-operative and Operative Management.....	104
2.2.6.5 Post-operative Management .....	105
2.3 Documentation of Operative and Post-operative Clinical Variables .....	107
2.3.1 Operative Duration and Duration of Ischaemia.....	107
2.3.2 Other Clinical Variables .....	107
2.4 Blood Sample Collection and Storage Protocol .....	108
2.5 Measurement of Pre-operative PMN CD11b, Fc $\gamma$ RI (CD64) and Fc $\gamma$ RIIIb (CD16b) Expression.....	111
2.5.1 Direct Immunofluorescence Staining .....	111
2.5.2 Flow Cytometry .....	113
2.6 Determination of Fc $\gamma$ RIIa (CD32a) and Fc $\gamma$ RIIIb (CD16b) Genotypes .....	115
2.6.1 Isolation of Deoxyribonucleic Acid (DNA) From Whole Blood .....	115
2.6.2 Fc $\gamma$ RIIa (CD32a) Genotyping .....	115
2.6.3 Fc $\gamma$ RIIIb (CD16b) Genotyping.....	117

2.7 Plasma Cytokine Assays .....	120
2.8 Determination of Neuroendocrine Response to Surgical Interventions .....	123
2.8.1 Twenty-Four Hour Urine Collections.....	123
2.8.2 Automated Chemiluminescent Immunoassay for Urinary Free Cortisol (UFC).....	124
2.8.3 Urinary Catecholamine Assay by High Performance Liquid Chromatography (HPLC) .....	125
2.8.4 Validity of Measures of Neuroendocrine Response .....	125
2.9 Determination of Pre-operative Nutritional Status.....	127
2.9.1 The Mini Nutritional Assessment (MNA).....	127
2.9.2 Dual Energy X-Ray Absorptiometry (DEXA) .....	128
2.10 Pre-operative Psychological Assessments.....	133
2.10.1 Measures of Depression.....	134
2.10.1.1 Beck Depression Inventory-II (BDI-II) .....	134
2.10.1.2 Center for Epidemiological Studies-Depression Scale (CES-D).....	135
2.10.2 Measurement of Trait Anxiety .....	136
2.10.2.1 Spielberger Trait-Anxiety Scale (STAI Form Y-2).....	136
2.11 Outcome Measures .....	139
2.11.1 Systemic Inflammatory Response Syndrome (SIRS) Score and Duration .....	139
2.11.1.1 SIRS Score.....	139
2.11.1.2 SIRS Duration.....	141
2.11.2 Sepsis Occurrence.....	141
2.11.3 Occurrence of Infection .....	142
2.11.4 Measures of General Post-operative Morbidity.....	143

2.11.4.1 Occurrence of Moderate/Severe Post-operative Complications(s).....	143
2.11.4.2 Maximum APACHE II Score .....	143
2.11.4.3 ICU and Post-operative Length of Stay (LOS).....	144
2.11.5 Health-related Quality of Life (HRQoL).....	144
2.11.5.1 Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey .....	144
2.12 Documentation of Potential Confounding Clinical Factors .....	147
2.12.1 Peri-operative Pharmacotherapy.....	147
2.13 Statistical Analyses.....	149
2.13.1 Overview of Statistical Analyses Performed.....	149
2.13.2 Relationship Between Cytokines and Sepsis.....	151

## **CHAPTER 3: RESULTS**

3.1 Operative Outcomes .....	152
3.1.1 Operative and Post-operative Clinical Variables.....	152
3.1.2 Outcome Measures of General Post-operative Morbidity and Mortality ....	153
3.1.3 Outcome Measures of SIRS, Sepsis and Infection .....	155
3.1.4 Potential Confounding Factors .....	157
3.1.4.1 $\beta$ -Blocker Administration .....	157
3.1.4.2 Corticosteroid Administration .....	157
3.2 Operative Duration and Duration of Ischaemia - Association with Clinical Outcomes.....	159
3.2.1 Associations with SIRS .....	159
3.2.2 Associations with Sepsis .....	159
3.2.3 Associations with Measures of General Post-operative Morbidity .....	159

3.3 Immunological Parameters.....	161
3.3.1 Pre-operative PMN CD11b, Fc $\gamma$ RI (CD64) and Fc $\gamma$ RIIb (CD16b) Expression and Associations with Clinical Outcomes .....	161
3.3.1.1 Associations with SIRS .....	162
3.3.1.2 Associations with Sepsis.....	162
3.3.2 Fc $\gamma$ R Genotypes and Associations with Clinical Outcomes .....	163
3.3.2.1 Fc $\gamma$ RIIa (CD32a) Genotypes and Associations with Clinical Outcomes .....	163
3.3.2.2 Fc $\gamma$ RIIb (CD16b) Genotypes and Associations with Clinical Outcomes .....	165
3.3.3 Plasma Cytokines .....	166
3.3.3.1 Cytokine Responses to Open AAA Repair Compared to EVAR .....	166
3.3.3.2 Prediction of Sepsis from Plasma Cytokine Values .....	168
3.4 Pre-operative Nutritional Status and Associations with Clinical Outcome.....	170
3.4.1 Body Mass Index (BMI) and DEXA Derived Measures of Body Composition.....	170
3.4.1.1 Associations with SIRS .....	170
3.4.1.2 Associations with Sepsis.....	171
3.4.1.3 Associations with Measures of General Post-operative Morbidity .....	171
3.4.2 Nutritional Status Classified by Mini Nutritional Assessment (MNA).....	173
3.4.2.1 Associations with SIRS .....	174
3.4.2.2 Associations with Sepsis.....	174
3.4.2.3 Associations with Measures of General Post-operative Morbidity .....	174
3.5 Neuroendocrine Responses to Surgical Intervention .....	175
3.5.1 Reporting of Data and Statistical Considerations.....	175

3.5.2 Time Course of Neuroendocrine Responses .....	176
3.5.2.1 Urinary Free Cortisol (UFC).....	176
3.5.2.1.1 Open AAA Repair.....	176
3.5.2.1.2 EVAR.....	177
3.5.2.1.3 Lower Limb Revascularisation .....	177
3.5.2.2 Urinary Adrenaline Excretion.....	178
3.5.2.2.1 Open AAA Repair.....	178
3.5.2.2.2 EVAR.....	178
3.5.2.2.3 Lower Limb Revascularisation .....	179
3.5.2.3 Urinary Noradrenaline Excretion.....	179
3.5.2.3.1 Open AAA Repair.....	179
3.5.2.3.2 EVAR.....	180
3.5.2.3.3 Lower Limb Revascularisation .....	180
3.5.3 Neuroendocrine Responses in Open AAA Repair Compared to EVAR....	181
3.5.3.1 Urinary Free Cortisol (UFC).....	181
3.5.3.2 Urinary Adrenaline Excretion.....	181
3.5.3.3 Urinary Noradrenaline Excretion.....	182
3.5.3.4 Post-operative Analgesia .....	183
3.5.4 Associations Between Neuroendocrine Reponses and Clinical Outcome...	183
3.5.4.1 Associations with SIRS .....	184
3.5.4.2 Associations with Sepsis.....	184
3.5.4.3 Associations with Measures of General Post-operative Morbidity .....	185
3.6 Psychological Measures and Influence on Surgical Response and Outcome ...	186
3.6.1 Pre-operative Depression.....	186
3.6.1.1 Incidence of Pre-operative Depression .....	186

3.6.1.1.1 Classification by BDI-II.....	186
3.6.1.1.2 Classification by CES-D .....	186
3.6.1.2 Depression and Measures of General Post-operative Morbidity .....	187
3.6.1.3 Depression and Health-related Quality of Life.....	188
3.6.1.4 Depression and Post-operative SIRS .....	191
3.6.1.5 Depression and Post-operative Sepsis .....	191
3.6.1.6 Depression and the Post-operative Neuroendocrine Response to Surgery.....	192
3.6.2 Pre-operative Trait Anxiety .....	192
3.6.2.1 Association with Neuroendocrine Responses.....	192

## **CHAPTER 4: DISCUSSION**

4.1 General Limitations of Current Study .....	193
4.1.1 Sample Size .....	193
4.1.2 Inclusion Criteria .....	194
4.1.3 Exclusion Criteria.....	194
4.1.4 Standardisation of Clinical Protocols .....	196
4.2 Consensus Definitions of SIRS and Sepsis .....	198
4.2.1 Definition of SIRS .....	198
4.2.2 Definition of Sepsis .....	199
4.3 Incidence of Clinical Outcomes in Current Study.....	201
4.3.1 SIRS.....	201
4.3.2 Sepsis .....	201
4.3.3 General Post-operative Morbidity and Mortality .....	202
4.4 Rationale for Separation of Study Cohort .....	203

4.5 Operative Variables - Relationship with Clinical Outcomes .....	204
4.5.1 SIRS.....	204
4.5.2 Sepsis.....	205
4.5.3 Measures of General Post-operative Morbidity.....	206
4.6 Immunological Parameters.....	207
4.6.1 Pre-operative PMN CD11b, Fc $\gamma$ RI (CD64) and Fc $\gamma$ RIIb (CD16b) - Relationship with Clinical Outcome .....	207
4.6.1.1 PMN CD11b .....	207
4.6.1.2 PMN Fc $\gamma$ RI (CD64).....	209
4.6.1.3 PMN Fc $\gamma$ RIIb (CD16b) .....	209
4.6.2 Fc $\gamma$ R Genotypes and Clinical Outcomes .....	211
4.6.3 Cytokine Responses in Major Vascular Surgery .....	213
4.6.3.1 Cytokine Levels Amongst Collective Aortic Aneurysm Repair Cohort .....	213
4.6.3.2 Prediction of Sepsis from Plasma Cytokine Values .....	216
4.7 Pre-operative Nutritional Status and Relationship to Clinical Outcomes .....	217
4.7.1 Pre-operative Nutritional Status .....	217
4.7.2 BMI and DEXA Derived Measures of Nutritional Status - Relationship to Clinical Outcome.....	218
4.7.2.1 SIRS .....	218
4.7.2.2 Measures of General Post-operative Morbidity .....	220
4.7.2.3 Sepsis .....	221
4.7.3 MNA Classification of Nutritional Status - Relationship to Clinical Outcome .....	222
4.8 Neuroendocrine Response to Surgical Intervention.....	223

4.8.1 Potential Limitations of Neuroendocrine Analyses .....	223
4.8.1.1 Administration of Exogenous Catecholamines.....	223
4.8.1.2 Renal Function .....	224
4.8.2 Time Course of Neuroendocrine Responses .....	224
4.8.2.1 Urinary Free Cortisol (UFC).....	224
4.8.2.2 Adrenaline.....	225
4.8.2.3 Noradrenaline.....	226
4.8.3 Association Between Neuroendocrine Responses and Clinical Outcome...	226
4.8.3.1 SIRS .....	226
4.8.3.2 Sepsis .....	227
4.8.3.3 Measures of General Post-operative Morbidity.....	229
4.9 Psychological Measures and Influence on Surgical Response and Outcomes...	230
4.9.1 Incidence of Pre-operative Depression.....	230
4.9.2 Depression and General Post-operative Morbidity .....	231
4.9.3 Depression and Health-related Quality of Life.....	232
4.9.4 Depression and Post-operative SIRS and Sepsis.....	235
4.9.5 Depression and Neuroendocrine Responses to Surgery .....	236
4.9.6 Pre-operative Trait Anxiety and Neuroendocrine Response to Surgery .....	237
4.10 Immunological and Neuroendocrine Response in Open AAA Repair Compared to EVAR .....	239
4.10.1 Comparability of ‘Open’ and EVAR Cohorts .....	239
4.10.2 The Immuno-inflammatory Response in Open AAA Repair Compared to EVAR .....	241
4.10.2.1 Cytokine Responses .....	241
4.10.2.2 SIRS .....	242

4.10.3 The Neuroendocrine Response in Open AAA Repair Compared to EVAR .....	243
--	-----

## **CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS**

5.1 SIRS and Sepsis - Value and Limitations .....	245
5.2 Immunological Parameters.....	247
5.2.1 PMN Integrin and Immunoglobulin G Fc Receptors .....	247
5.2.2 Fc $\gamma$ R Genotypes.....	248
5.2.3 Cytokines .....	249
5.3 Pre-operative Nutritional Status .....	250
5.4 Neuroendocrine Responses to Surgical Intervention .....	251
5.5 Psychological Measures and Influence on Surgical Response and Outcome ....	252
5.5.1 Pre-operative Depression and Post-operative Outcomes.....	252
5.5.2 Pre-operative Depression and Neuroendocrine Responses to Surgery .....	253
5.5.3 Pre-operative Trait Anxiety and Neuroendocrine Responses to Surgery ....	254
5.6 Immunological and Neuroendocrine Responses in Open AAA Repair Compared to EVAR .....	255
5.6.1 The Immuno-inflammatory Response .....	255
5.6.2 The Neuroendocrine Response .....	255
5.7 Concluding Remarks .....	257

## **APPENDICES**

Appendix 1: Comorbidity Scoring .....	259
Appendix 2: Mini Nutritional Assessment.....	263
Appendix 3: Psychological Questionnaires.....	265

Appendix 4: Post-operative Outcome Scoring ..... 272

Appendix 5: Abbreviations ..... 283

**REFERENCES** ..... 292

## **Abstract**

### ***Background***

Prediction of post-operative systemic inflammatory response syndrome (SIRS) and sepsis would assist risk stratification prior to major vascular surgery, and may positively affect morbidity and mortality rates. Reciprocal regulation exists between immuno-inflammatory and neuroendocrine responses. Like inflammatory events, the neuroendocrine stress response is an important component of surgical pathophysiology. Psychological variables may influence neuroendocrine function and therefore modulate the neuroendocrine response to major vascular surgery. Comparison of both immuno-inflammatory and neuroendocrine responses to open abdominal aortic aneurysm (AAA) repair and endovascular aneurysm repair (EVAR) would enhance understanding of biological mechanisms underlying the differing clinical outcomes from these surgical approaches.

### ***Aims***

The aims of the current study were: (1) to identify relationships between post-operative SIRS and sepsis and markers of immunological, neuroendocrine, nutritional and psychological status; (2) to examine relationships between psychological variables and neuroendocrine responses to surgery; and (3) to identify differences in immunological and neuroendocrine responses to open AAA repair compared with EVAR.

## **Methods**

A prospective cohort study was performed involving patients undergoing elective open AAA repair ( $n = 36$ ), EVAR ( $n = 17$ ) and lower limb revascularisation ( $n = 17$ ). Pre-operative neutrophil expression of CD11b and CD16b was determined, and CD32a and CD16b genotyping performed. Plasma cytokines were assayed pre-operatively, during maximal intra-operative ischaemia ( $T_0$ ), and 4, 24 and 72 hours following  $T_0$ . Twenty-four hour urinary free cortisol (UFC) and catecholamine excretion was assayed pre-operatively [T(pre-op)], from anaesthetic induction [T(0-24)] and 72 hours later [T(72-96)]. Pre-operative nutritional status was assessed by dual energy x-ray absorptiometry (DEXA). Pre-operative depression and trait anxiety were evaluated using self-report inventories. SIRS severity and duration within five post-operative days and sepsis within 30 days were documented.

## **Results**

A positive correlation was identified between CD11b expression and SIRS severity score amongst EVAR patients. Neither CD32a nor CD16b genotypes were associated with sepsis. Fluctuations in IL-6, IL-8, and IL-10 were frequently observed in association with AAA repair whereas elevations in TNF- $\alpha$ , IL-1 $\beta$  and IL-12p70 were infrequent. IL-10 production predicted sepsis in this cohort but could not be used to confidently predict sepsis for any individual. Negative correlations were identified between fat free mass (FFM) and both SIRS score following open AAA repair and SIRS duration following EVAR. A negative correlation existed between skeletal muscle mass (SMM) and both SIRS score and duration following open AAA repair. SIRS duration was significantly longer amongst non-depressed compared to depressed EVAR subjects categorised by the Beck Depression Inventory - II (BDI-

II), however no difference was apparent when the Center for Epidemiological Studies-Depression Scale (CES-D) was employed.

UFC excretion at T(0-24) was significantly greater amongst non-depressed compared to depressed subjects, but only when BDI-II classifications were used. Correlations between trait anxiety and neuroendocrine responses to surgery were weak and non-significant.

Open AAA repair stimulated greater production of IL-6, IL-8 and IL-10 than EVAR. Accordingly, SIRS was more frequent, severe and prolonged following open AAA repair. At T(72-96) both UFC and adrenaline excretion were greater amongst the open AAA than the EVAR cohort. These neuroendocrine responses were positively correlated with measures of SIRS and were significantly greater amongst those who developed sepsis.

## ***Conclusions***

Higher pre-operative CD11b may be associated with more severe SIRS following major vascular surgery. Lower pre-operative FFM and SMM are associated with more severe SIRS after AAA repair. Neuroendocrine responses reflect rather than predict post-operative SIRS and sepsis. No relationships between psychological parameters and neuroendocrine responses to surgery were identified. Robust evidence of a greater inflammatory response to open AAA repair than EVAR has clarified contradictory reports in existing literature.